Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, ...

FARGO — A new FDA approved drug, to help people with schizophrenia, will soon be accessible for medical officials to prescribe. It's called Cobenfy; a pill that will need to be taken twice a day.

The findings indicate that genetic assays intended to predict individual risk for opioid use disorder—such as the AvertD test, developed by AutoGenomics Inc. and recently approved by the FDA—are ...

European regulators approved Dupixent for COPD in July, but Regeneron and Sanofi have had to wait longer in the U.S., where the FDA requested additional efficacy data from the two trials. Over that ...

People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and Drug Administration Thursday approved a new kind of drug. Studies ...

The U.S. Food and Drug Administration (FDA) approved a novel antipsychotic schizophrenia drug late Thursday, marking the first new treatment in decades for the mental health condition that affects ...

No new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...

The U.S. Food and Drug Administration has approved a new drug for schizophrenia ... which is one of the 15 leading causes of disability worldwide, the FDA reports. Individuals with this disease ...

Meanwhile, thousands of patients allege in a lawsuit that drugs used for diabetes and weight loss have caused other health problems. The Washington Post: FDA Approves New Type Of Antipsychotic Drug, A ...

In this case, the main asset was KarXT (now known as Cobenfy), which as per today's FDA approval, became the first drug for the treatment of Schizophrenia with a novel mechanism of action to be ...

Tiffany Farchione, director of psychiatry in the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research. “This drug takes the first new approach to schizophrenia treatment in ...

Schizophrenia is estimated to impact approximately 2.8 million people in the U.S. The FDA approval of Cobenfy is supported by data from the EMERGENT clinical program, which includes three placebo ...